Overview

Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis

Status:
Completed
Trial end date:
2017-02-14
Target enrollment:
Participant gender:
Summary
The study investigates different criteria for remission based on MRI and circulating biomarkers for inflammation, cartilage, connective tissue and bone turnover in patients with axial spondyloarthritis treated with Golimumab. Furthermore, the study also investigates factors that affect disease activity, function and participation by use of different questionnaires.
Details
Lead Sponsor:
Professor Mikkel Østergaard
Susanne Juhl Pedersen
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Antibodies, Monoclonal
Golimumab